Barclays PLC Crispr Therapeutics Ag Call Options Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 15, 2024	SELL	$44.62 - $62.75 $3.75 Million - $5.27 Million	-84,000 Reduced 73.68%	30,000 $1.41 Million
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $4.45 Million - $5.93 Million	87,000 Added 322.22%	114,000 $6.16 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $1.52 Million - $2.23 Million	-25,000 Reduced 48.08%	27,000 $1.84 Million
Q4 2023 Feb 15, 2024	BUY	$38.62 - $72.18 $2.01 Million - $3.75 Million	52,000 New	52,000 $3.26 Million
Q4 2020 Feb 11, 2021	SELL	$79.67 - $173.23 $2.57 Million - $5.58 Million	-32,200 Reduced 92.8%	2,500 $383,000
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $816,144 - $2.02 Million	34,700 New	34,700 $1.59 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.